From GlobeNewswire: 2025-02-19 05:00:00

Medigene AG has been granted a U.S. patent for its JOVI technology, which enriches T cells for cancer treatment. This patent strengthens the company’s End-to-End (E2E) Platform for TCR-guided therapies. Medigene’s expertise in T cell immunology allows for the development of safe and effective TCRs for therapies like TCR-TCE and TCR-NK. The innovative JOVI technology facilitates the comparison of TCR-expressing T cells, ensuring the creation of superior therapies. With over 29 patent families worldwide, Medigene continues to expand its portfolio to develop new 3S TCRs and advance its technologies for cancer treatment.



Read more at GlobeNewswire: Medigene AG Expands Patent Portfolio with Patent Grant for